Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advancements in Viral Hepatitis From EASL 2022

June 22-26, 2022; London, United Kingdom
Listen to expert insights from Nancy Reau, MD, on updates and new viral hepatitis data from EASL 2022, including HBV novel therapeutics in development, therapeutic vaccination for HBV, emerging treatments for HDV, HCV care cascade, and the need for HCC monitoring post HCV cure.
Nancy Reau, MD
Released: July 5, 2022

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:

  • Novel therapeutics for HBV
  • Therapeutic vaccination for HBV
  • Emerging treatment options for HDV
  • HCV care cascade
  • HCC monitoring after HCV cure

Information on this Educational Activity

Faculty

Nancy Reau, MD

Professor of Medicine
Chief,
Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received funds for research support paid to her institution from AbbVie and Gilead Sciences and consulting fees from AbbVie, Arbutus, Gilead Sciences, Intercept, and Salix.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Grace Wong, MD: use of an interactive decision support tool to guide screening for and treatment of HDV, from Clinical Care Options (CCO)

Grace LH Wong, MD Released: September 12, 2022

Dr Paul Kwo discusses evolving treatment options for hepatitis delta virus (HDV), from Clinical Care Options (CCO)

Paul Y. Kwo, MD Released: August 2, 2022

Download slides reviewing the latest data and guidance on approaches to managing patients with hepatitis delta virus (HDV), from Clinical Care Options (CCO)

person default Joseph (Patient) Maria Buti, MD person default Richard H. Davis, PA-C Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 25, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings